• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Legal Officer Stimart Tryn

    1/3/25 3:44:41 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABCL alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Stimart Tryn

    (Last) (First) (Middle)
    C/O ABCELLERA BIOLOGICS INC
    2215 YUKON STREET

    (Street)
    VANCOUVER A1

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    AbCellera Biologics Inc. [ ABCL ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Legal Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    01/01/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Share option (right to buy) $2.93 01/01/2025 A V 832,033 (1) 01/01/2035 Common Shares 832,033 $0 4,106,747 D
    Explanation of Responses:
    1. The shares subject to such option vest and become exercisable monthly in substantially equal installments over a four-year period, with the first tranche vested on January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
    Remarks:
    Tryn Stimart 01/03/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ABCL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABCL

    DatePrice TargetRatingAnalyst
    7/7/2025$5.00Outperform
    Leerink Partners
    8/20/2024Buy → Hold
    The Benchmark Company
    2/22/2024$9.00Hold → Buy
    The Benchmark Company
    12/5/2023$6.00Overweight
    KeyBanc Capital Markets
    11/6/2023Buy → Hold
    The Benchmark Company
    10/13/2023$20.00Overweight
    Piper Sandler
    2/28/2023Outperform
    Cowen
    12/15/2022$30.00Buy
    Goldman
    More analyst ratings

    $ABCL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AbCellera to Participate at Upcoming Investor Conferences in September

    AbCellera (NASDAQ:ABCL) today announced that the Company will participate in the following investor conferences: Wells Fargo Healthcare Conference, September 3-5, 2025 Morgan Stanley Annual Global Healthcare Conference, September 8-10, 2025 Visit AbCellera's Investor Relations website for additional information. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women's health, immunology, and oncology. For more information, please visit www.abcellera.com. View source version on businesswire.com: https://www.businesswire.com/news/home/2025

    8/12/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

    AbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our tran

    8/7/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

    AbCellera (NASDAQ:ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology

    7/7/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    SEC Filings

    View All

    SEC Form 10-Q filed by AbCellera Biologics Inc.

    10-Q - AbCellera Biologics Inc. (0001703057) (Filer)

    8/7/25 4:36:34 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    8/7/25 4:27:56 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - AbCellera Biologics Inc. (0001703057) (Filer)

    6/13/25 1:20:33 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners resumed coverage on AbCellera Biologics with a new price target

    Leerink Partners resumed coverage of AbCellera Biologics with a rating of Outperform and set a new price target of $5.00

    7/7/25 8:15:34 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics downgraded by The Benchmark Company

    The Benchmark Company downgraded AbCellera Biologics from Buy to Hold

    8/20/24 6:47:45 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Biologics upgraded by The Benchmark Company with a new price target

    The Benchmark Company upgraded AbCellera Biologics from Hold to Buy and set a new price target of $9.00

    2/22/24 6:35:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Thermopylae Holdings Ltd. bought $742,243 worth of shares (343,631 units at $2.16), increasing direct ownership by 0.62% to 56,143,640 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    3/11/25 6:42:57 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Montalbano John S. bought $57,500 worth of shares (25,000 units at $2.30), increasing direct ownership by 17% to 171,000 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    3/10/25 5:11:03 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Montalbano John S. bought $140,568 worth of shares (60,000 units at $2.34), increasing direct ownership by 70% to 146,000 units (SEC Form 4)

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    3/7/25 3:32:01 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Leadership Updates

    Live Leadership Updates

    View All

    AbCellera Announces Resignation of Board Member

    AbCellera (NASDAQ:ABCL) today announced that Peter Thiel has notified the Company of his intention to resign from the Company's Board of Directors for personal reasons, effective March 7, 2024. "AbCellera continues to expand the frontier of biotech, a nefariously difficult and vital field," said Peter Thiel. "I am proud to have helped them with their mission." Mr. Thiel joined AbCellera's Board of Directors in November 2020 and served as the Chairman of the Company's Nominating and Corporate Governance Committee. Effective March 7, 2024, Dr. Andrew Lo, a member of the Company's Board of Directors, will be appointed to the Nominating and Corporate Governance Committee of the Board of Dir

    2/23/24 4:30:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    DAMONA Pharmaceuticals Appoints John Reilly as Chief Executive Officer

    TORONTO, June 13, 2023 /PRNewswire/ -- DAMONA Pharmaceuticals, a preclinical biopharmaceutical company focused on the discovery and development of first-in-class small molecules for the treatment and prevention of cognitive symptoms associated with brain disorders and aging, today announced the appointment of John Reilly as the company's Chief Executive Officer and member of the Board of Directors. Mr. Reilly brings two decades of leadership experience building and creating value for biotechnology companies, with deep knowledge and expertise in corporate strategy, business dev

    6/13/23 7:59:57 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Announces Changes to Its Board of Directors

    AbCellera (NASDAQ:ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced changes to its Board of Directors with the appointment of Andrew W. Lo, Ph.D., as an independent director and the resignation of John Hamer, Ph.D. Changes are effective immediately. Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He will serve on the Audit and Compensation Committees of the Board of Directors. "Andrew is a d

    12/7/21 9:00:00 AM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AbCellera Biologics Inc.

    SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

    11/14/24 4:11:49 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by AbCellera Biologics Inc.

    SC 13G - AbCellera Biologics Inc. (0001703057) (Subject)

    2/14/24 4:21:54 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by AbCellera Biologics Inc. (Amendment)

    SC 13G/A - AbCellera Biologics Inc. (0001703057) (Subject)

    2/13/24 5:01:32 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Financials

    Live finance-specific insights

    View All

    AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms

    AbCellera (NASDAQ:ABCL) today announced financial results for the second quarter of 2025 and that dosing has begun in a Phase 1 clinical trial of ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "In the second quarter we hit two critical milestones, receiving authorization to initiate Phase 1 studies for both ABCL635 and ABCL575. I am pleased to announce today that we have successfully begun dosing the first participants in the Phase 1 study of ABCL635. This is a landmark achievement for AbCellera, one that completes our tran

    8/7/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025

    AbCellera (NASDAQ:ABCL) will announce its second quarter 2025 financial results on Thursday, August 7, 2025, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the conference call. About AbCellera Biologics Inc. AbCellera (NASDAQ:ABCL) discovers and develops antibody medicines for indications across therapeutic areas including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera's platform integrates technology

    7/7/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbCellera Reports Q1 2025 Business Results

    AbCellera (NASDAQ:ABCL) today announced financial results for the first quarter of 2025. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated. "After completion of a successful first quarter, we are excited to introduce ABCL635 as a potential first-in-class antibody for the non-hormonal treatment of vasomotor symptoms (hot flashes) associated with menopause. ABCL635 is positioned as a next-generation neurokinin 3 receptor (NK3R) antagonist with an improved safety profile and convenient dosing regimen. If successful, we believe it has the potential to be a highly differentiated product in a large and established market," said Carl Hansen, P

    5/8/25 4:05:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABCL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hayden Michael R

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    7/1/25 3:13:15 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Montalbano John S.

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    6/16/25 5:32:00 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lo Andrew

    4 - AbCellera Biologics Inc. (0001703057) (Issuer)

    6/16/25 5:30:33 PM ET
    $ABCL
    Biotechnology: Pharmaceutical Preparations
    Health Care